News

Earlier this week, the Wall Street Journal reported that Johnson & Johnson is in discussions to acquire Shockwave Medical, a medical device manufacturer specializing in cardiovascular treatments. This potential move suggests J&J’s interest in expanding its presence in the cardiovascular device market.

Shockwave Medical, known for its heart disease treatment devices, currently holds a market capitalization of approximately $11 billion, as per LSEG data.

According to sources familiar with the matter cited in the report, a deal could be reached in the upcoming weeks if negotiations progress smoothly, though the possibility of another interested party emerging remains. However, the report did not disclose the deal’s value.

This news from WSJ follows previous speculation regarding a bid for Shockwave Medical, with Bloomberg News reporting last year that Boston Scientific was contemplating an offer for the heart device manufacturer.

Shockwave Medical’s flagship product employs shockwaves to dissolve calcified plaque in heart vessels, a method akin to the treatment of kidney stones.

Johnson & Johnson expressed its intent last year to seek mergers or acquisitions that could enhance its cardiovascular product portfolio, indicating a preference for smaller-scale “tuck-in” acquisitions in the future. In 2022, the company notably acquired heart pump manufacturer Abiomed for $16.6 billion.

© Johnson & Johnson